CD8A and neoplasm: Our present AP-MS pipeline is, however, quite demanding in terms of T cell numbers, and its application to the PD-1+TCF1+ subpopulation of CD8+ TILs that respond to anti-PD-1 treatment will require hundreds of tumor-bearing PD-1-OST mice to isolate such TILs in sufficient number.